*	OR T2 T4 T3
R1	AND Arg1:T1 Arg2:T2	
R2	Has_negation Arg1:T7 Arg2:T8	
R3	Has_negation Arg1:T6 Arg2:T8	
R4	AND Arg1:T1 Arg2:T6	
R5	Has_value Arg1:T10 Arg2:T11	
R6	Has_value Arg1:T14 Arg2:T15	
*	OR T19 T16
*	OR T16 T17
R7	Has_negation Arg1:T18 Arg2:T20	
R8	AND Arg1:T12 Arg2:T10	
R9	AND Arg1:T22 Arg2:T14	
*	OR T12 T22
R10	Has_qualifier Arg1:T22 Arg2:T16	
R11	Has_qualifier Arg1:T22 Arg2:T18	
R12	Has_value Arg1:T24 Arg2:T25	
R13	Has_index Arg1:T26 Arg2:T27	
R14	Has_temporal Arg1:T24 Arg2:T26	
R15	Has_value Arg1:T28 Arg2:T29	
R16	Has_value Arg1:T31 Arg2:T33	
R17	AND Arg1:T32 Arg2:T31	
R18	Has_multiplier Arg1:T32 Arg2:T30	
R19	Has_value Arg1:T34 Arg2:T35	
R20	Has_index Arg1:T36 Arg2:T37	
R21	Has_temporal Arg1:T34 Arg2:T36	
R22	Has_context Arg1:T38 Arg2:T39	
R23	Has_qualifier Arg1:T45 Arg2:T44	
R24	Has_qualifier Arg1:T50 Arg2:T49	
R25	AND Arg1:T46 Arg2:T50	
R26	Has_index Arg1:T40 Arg2:T41	
R27	Has_temporal Arg1:T38 Arg2:T40	
*	OR T38 T46
*	OR T55 T54
R28	Has_temporal Arg1:T55 Arg2:T56	
R29	Has_value Arg1:T55 Arg2:T58	
R30	AND Arg1:T51 Arg2:T55	
R31	Has_index Arg1:T56 Arg2:T59	
*	OR T62 T61
R32	AND Arg1:T62 Arg2:T60	
R33	AND Arg1:T1 Arg2:T7	
R34	AND Arg1:T51 Arg2:T52	
R35	AND Arg1:T63 Arg2:T60	
R36	AND Arg1:T64 Arg2:T60	
T1	Condition 6 9	HCC
T2	Procedure 33 42	radiology
T3	Procedure 44 53	histology
T4	Procedure 58 66	cytology
T6	Condition 127 134;68 81	subtype fibrolamellar
T7	Condition 87 134	mixed hepatocellular/cholangiocarcinoma subtype
T8	Negation 140 152	not eligible
T10	Measurement 159 195	Barcelona Clinic Liver Cancer (BCLC)
T11	Value 196 203	Stage C
T12	Condition 204 211	disease
T13	Context_Error 204 211	disease
T14	Measurement 215 219	BCLC
T15	Value 220 227	Stage B
T16	Qualifier 240 272	amenable to locoregional therapy
T17	Qualifier 276 310	refractory to locoregional therapy
T18	Qualifier 319 360	amenable to a curative treatment approach
T19	Negation 236 239	not
T20	Negation 315 318	not
T22	Condition 228 235	disease
T23	Context_Error 228 235	disease
T24	Measurement 368 378;381 392	Child-Pugh liver score
T25	Value 379 380	A
T26	Temporal 393 412	within 7 days prior
T27	Reference_point 416 446	first dose of study medication
T28	Observation 454 469	life expectancy
T29	Value 473 482	>3 months
T30	Multiplier 488 500	at least one
T32	Condition 512 518	lesion
T31	Measurement 528 546	RECIST version 1.1
T33	Value 501 511	measurable
T34	Measurement 582 642	Eastern Cooperative Oncology Group (ECOG) performance status
T35	Value 646 652	0 or 1
T36	Temporal 663 682	within 7 days prior
T37	Reference_point 686 730	receiving the first dose of study medication
T38	Procedure 757 769	radiographic
T39	Observation 747 756;770 781	objective progression
T40	Temporal 782 797	during or after
T41	Reference_point 798 856	treatment with sorafenib or oxaliplatin-based chemotherapy
T42	Drug 813 822	sorafenib
T43	Drug 826 837	oxaliplatin
T44	Qualifier 813 843	sorafenib or oxaliplatin-based
T45	Procedure 844 856	chemotherapy
T46	Condition 866 877	intolerance
T47	Drug 881 890	sorafenib
T48	Drug 894 905	oxaliplatin
T49	Qualifier 881 911	sorafenib or oxaliplatin-based
T50	Procedure 912 924	chemotherapy
T51	Person 926 932	Female
T52	Condition 949 971	childbearing potential
T54	Measurement 1008 1022;993 998	pregnancy test urine
T55	Measurement 1002 1022	serum pregnancy test
T56	Temporal 1023 1044	within 72 hours prior
T58	Value 984 992	negative
T59	Reference_point 1048 1089	receiving the first dose of study therapy
T60	Procedure 1164 1186	adequate contraception
T61	Person 1102 1106	male
T62	Person 1091 1097	Female
T63	Grammar_Error 1098 1101	and
T64	Condition 1123 1145	reproductive potential
T66	Non-query-able 1091 1328	Female and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication
T67	Post-eligibility 926 1089	Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study therapy
T68	Post-eligibility 1091 1328	Female and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication
